


Current Status of the Claims:

This listing of claims will replace the listing of claims in the application:

Listing of Claims:

1. (Cancelled).
- 2-4. (Withdrawn).
5. (Cancelled).
- 6-8. (Withdrawn).
9. (Cancelled).
10. (Previously Presented) The unit oral dosage form of claim 16 wherein said composition is in the form of a tablet.
11. (Previously Presented) The unit dosage form of claim 16 wherein the hydroxypropyl methyl cellulose polymer matrix is present in an amount of from about 20% to 40% by weight of this composition.
12. (Previously Presented) The unit dosage form of claim 16 wherein said polymer matrix has a viscosity of from about 100 to about 100,000 cps.
13. (Previously Presented) The unit dosage form of claim 10 wherein said active ingredient is present in an amount of 200 mg to 400 mg.
- 14-15. (Withdrawn).
16. (Previously Presented) A unit oral dosage form comprising a composition containing from about 25 to 600 mg of an active ingredient selected from the group consisting of a compound of the formula



and a pharmaceutically acceptable salt thereof,


from about 15% to about 50% of weight of said composition of a hydroxypropyl methyl cellulose hydrophilic slow release polymer matrix.

17. (Previously Presented) The unit dosage form of claim 16 wherein said dosage form contains a pharmaceutically carrier composition containing calcium phosphate.

18. (Previously Presented) The unit dosage form of claim 17 wherein said carrier is present in an amount of from about 40% to 60% by weight of said composition.

19-25. (Withdrawn)

26. (Previously Presented) A pharmaceutical composition comprising:
a pre-determined dosage amount of an active ingredient selected from a compound of Formula I



and pharmaceutically acceptable salts thereof; and

a sustained release vehicle.

27. (Previously Presented) The composition of claim 26, wherein said pre-determined dosage amount of the active ingredient is between about 200-600 mg.

28. (Previously Presented) The composition of claim 26, wherein said pre-determined dosage amount of the active ingredient is about 100 mg, about 200 mg, about 400 mg, or about 600 mg.

29. (Previously Presented) The composition of claim 26, wherein said pharmaceutically acceptable salts are selected from the group consisting of


hydrochloride, phosphate, citrate, fumarate, maleate, succinate, pamoate, and sulfate acid-addition salts.

30. (Previously Presented) The composition of claim 26, wherein said compound of formula I is formulated with a sustained release vehicle in an oral dosage composition which, following administration of the composition to a mammalian subject provides not less than 10% of the compound of formula I released within 15 minutes and not less than 50% of the compound of formula I released within 4 hours and not less than 85% by weight of the compound of formula I released within 12 hours.

31. (Previously Presented) The composition of claim 26, wherein said sustained release vehicle is a sustained release polymer.

32. (Previously Presented) The composition of claim 26, wherein said sustained release polymer is a polyacrylic acid polymer or hydroxypropylmethyl cellulose polymer.

33. (Previously Presented) A pharmaceutical composition comprising:
a pre-determined dosage amount of an active ingredient selected from a compound of Formula I




and pharmaceutically acceptable salts thereof; and
a sustained release vehicle, said composition formulated in an oral dosage form having a sustained release dissolution profile using USP1 apparatus, 20 mesh baskets, 75 rpm, 900 ml phosphate buffer pH 6.8 ± 0.05 , $37^\circ\text{C} \pm 0.05^\circ\text{C}$ wherein between about 9.2%-17.7% of said compound is released within approximately 0.25 hours.

34. (Previously Presented) The composition of claim 33, wherein said pre-determined dosage amount of the active ingredient is between about 200-600 mg.

35. (Previously Presented) The composition of claim 33, wherein said sustained release vehicle is a sustained release polymer.

36. (Previously Presented) The composition of claim 35, wherein said sustained release polymer is a polyacrylic acid polymer or hydroxypropylmethyl cellulose polymer.


37. (Previously Presented) A pharmaceutical composition comprising:
a pre-determined dosage amount of an active ingredient selected from a compound of Formula I



and pharmaceutically acceptable salts thereof; and
a sustained release vehicle, said composition formulated in an oral dosage form having a sustained release dissolution profile using USP1 apparatus, 20 mesh baskets, 75 rpm, 900 ml phosphate buffer pH 6.8 ± 0.05 , $37^\circ\text{C} \pm 0.05^\circ\text{C}$ wherein between about 42.9%-57.4% of said compound is released within approximately 4.0 hours.

38. (Previously Presented) The composition of claim 37, wherein said pre-determined dosage amount of the active ingredient is between about 200-600 mg.
39. (Previously Presented) The composition of claim 37, wherein said sustained release vehicle is a sustained release polymer.
40. (Previously Presented) The composition of claim 39, wherein said sustained release polymer is a polyacrylic acid polymer or hydroxypropylmethyl cellulose polymer.
41. (Previously Presented) A pharmaceutical composition comprising:


a pre-determined dosage amount of an active ingredient selected from a compound of Formula I



and pharmaceutically acceptable salts thereof; and
a sustained release vehicle, said composition formulated in an oral dosage form having a sustained release dissolution profile using USP1 apparatus, 20 mesh baskets, 75 rpm, 900 ml phosphate buffer pH 6.8 ± 0.05 , $37^\circ\text{C} \pm 0.05^\circ\text{C}$ wherein between about 65.7%-99.9% of said compound is released within approximately 12.0 hours.

42. (Previously Presented) The composition of claim 41, wherein said pre-determined dosage amount of the active ingredient is between about 200-600 mg.

43. (Previously Presented) The composition of claim 41, wherein said sustained release vehicle is a sustained release polymer.
44. (Previously Presented) The composition of claim 43, wherein said sustained release polymer is a polyacrylic acid polymer or hydroxypropylmethyl cellulose polymer.
45. (Previously Presented) A pharmaceutical composition comprising:
a pre-determined dosage amount of an active ingredient selected from a compound of Formula I



- and pharmaceutically acceptable salts thereof; and
a sustained release vehicle, which following administration of the composition to a mammalian subject provides a maximum plasma concentration (C_{max}) of said compound in the subject that is less than about 37% of a C_{max} provided in a control subject after administration of the same amount of said compound in a rapid release formulation.
46. (Previously Presented) The composition of claim 45, wherein said pre-determined dosage amount of the active ingredient is between about 200-600 mg.
47. (Previously Presented) The composition of claim 45, wherein said sustained release vehicle is a sustained release polymer.
48. (Previously Presented) The composition of claim 43, wherein said sustained release polymer is a polyacrylic acid polymer or hydroxypropylmethyl cellulose polymer.
49. (Previously Presented) The composition of claim 45, which following administration of the composition to a mammalian subject provides a maximum plasma concentration (C_{max}) of said compound in the subject that is between about 27%-37% of a C_{max} provided in a control subject after administration of the same amount of said compound in a rapid release formulation.